Sarepta Therapeutics
SRPT
328 hedge funds and large institutions have $5.71B invested in Sarepta Therapeutics in 2022 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 94 increasing their positions, 122 reducing their positions, and 63 closing their positions.
64% more call options, than puts
Call options by funds: $135M | Put options by funds: $82.1M
1.21% more ownership
Funds ownership: 82.61% → 83.82% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
4% less funds holding
Funds holding: 343 → 328 (-15)
12% less capital invested
Capital invested by funds: $6.48B → $5.71B (-$771M)
16% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 63
23% less repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 122
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$158M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$62.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$51.6M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$42.1M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$35.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$103M |
| 2 |
RI
RTW Investments
New York
|
-$52.4M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$45.4M |
| 4 |
Sands Capital Management
Arlington,
Virginia
|
-$44.5M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$44.4M |
SRPT Hedge Fund Activity: Q1 2022 in Review
328 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2022, worth a combined $5.71B — down 12% from $6.48B a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of SRPT and 53 opened new positions — a net loss of 10 holders — while 122 trimmed existing stakes and 94 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $158M. The largest seller was Fidelity Investments, cutting an estimated $103M.
- 328 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2022, down from 343 in Q4 2021.
- Funds reported $5.71B of Sarepta Therapeutics stock for Q1 2022, down 12% quarter-over-quarter.
- 53 funds opened new Sarepta Therapeutics positions in Q1 2022 and 63 closed out, a net change of -10 holders.
- The largest Sarepta Therapeutics buyer in Q1 2022 was EcoR1 Capital, an estimated $158M added.
- The largest Sarepta Therapeutics seller in Q1 2022 was Fidelity Investments, an estimated $103M sold.
Based on aggregated 13F filings for Q1 2022.